在生物定义的阿尔茨海默氏症中,区域化变化和代谢相关物使用多式联络方法
Marco Michelutti1, Valentina Cenacchi1, Tiziana Lombardo1
1Neurology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
Journal of Alzheimer's disease : JAD
|October 29, 2025
概括
胰岛和脑内皮层的转化指数 (GI) 变化可能成为早期阿尔茨海默病 (AD) 的生物标志物. 这些胃肠道变化与大脑新陈代谢和认知功能相关,表明潜在的诊断和治疗价值.
科学领域:
- 神经成像是一种神经成像.
- 生物标志物发现发现
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 基于表面的形态学 (SBM) 度量,如化指数 (GI),显示为阿尔茨海默病 (AD) 的早期生物标志物具有前途.
- 在AD中微妙的皮质变化可以使用SBM检测到,有助于早期诊断.
研究的目的:
- 为了研究生物学定义的AD患者和非AD认知障碍参与者之间的GI差异.
- 探索GI,区域代谢 (FDG-PET),皮质厚度 (MRI) 和认知表现 (MoCA) 之间的相关性.
主要方法:
- 对36名AD和15名非AD参与者的T1加权MRI和FDG-PET扫描进行了回顾性分析.
- 使用基于SPM的全脑和ROI图谱分析计算GI.
- 从ROI提取标准化摄入值比率 (SUVR) 并通过MoCA评估认知表现.
主要成果:
- 阿尔茨海默病的参与者显示,胰岛肠道和代谢吸收减少,肠道内/副海马肠道增加.
- 岛屿GI与新陈代谢,皮质厚度和MoCA分数正相关.
- 副海马肠道肠道与皮层厚度相反相关.
结论:
- 在胰岛和内腔皮层的特定区域的消化道变化是AD的特征.
- 胃肠道和新陈代谢之间的新相关性表明,在阿尔茨海默病中,皮层折叠与突触功能障碍之间的联系机制.
- 胃肠道显示出作为阿尔茨海默病的有价值的早期生物标志物的潜力,对诊断和治疗有影响.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806


